| Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. | |
| | |
MedLine Citation:
|
PMID: 7604798 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this study was to assess the effects of fluvastatin and pravastatin on lipid profiles and urinary thromboxane (TX) A2 metabolites (11-dehydro TXB2 and 2,3-dinor TXB2) in patients with type IIa hypercholesterolemia. A total of 20 patients (13 men, 7 women; mean age 53 +/- 9 years) with primary type IIa hypercholesterolemia (Fredrickson's classification) in a 4-week, double-blind, parallel-group study were randomized to fluvastatin or pravastatin, both at 40 mg once daily (at bedtime), after a single-blind, 4-week, placebo run-in period. Total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides were measured after placebo (baseline) and after 4 weeks of double-blind treatment. Thromboxane metabolites were measured at the same time points, using an enzyme immunoassay kit, in 12 hr urine samples. At baseline, the mean +/- SD levels of total cholesterol, LDL-C, triglycerides, and HDL-C were: 292 +/- 23, 213 +/- 47, 186 +/- 119 and 41 +/- 17 mg/dL with fluvastatin; and 301 +/- 40, 212 +/- 40, 150 +/- 124 and 43 +/- 10 mg/dL with pravastatin, respectively. Baseline thromboxane-metabolite levels were positively and significantly (p < 0.04) correlated with levels of total cholesterol, but not LDL-C. Compared with baseline, total cholesterol and LDL-C were significantly (p < 0.01) decreased by 27% and 30% with fluvastatin, and by 23% and 31% with pravastatin, respectively. HDL-C increased from 41 +/- 17 to 59 +/- 25 mg/dL with fluvastatin, and from 43 +/- 10 to 46 +/- 12 mg/dL with pravastatin.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
M Milani; C Cimminiello; B Merlo; M Lorena; G Arpaia; G Bonfardeci |
Related Documents
:
|
21474898 - Cardiovascular disease risk factors in adolescent british south asians and whites: a pi... 19225968 - Effects of kiwifruit consumption on serum lipid profiles and antioxidative status in hy... 8247108 - The relationship of high-density lipoprotein cholesterol to obesity, drinking and smoki... 17996508 - Prevalence of low high-density lipoprotein cholesterol in patients with documented coro... 1900738 - Influence of diet and calorie restriction on the initiation and promotion of skin carci... 8120678 - Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol, on ... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: The American journal of cardiology Volume: 76 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1995 Jul |
Date Detail:
|
Created Date: 1995-08-10 Completed Date: 1995-08-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 51A-53A Citation Subset: AIM; IM |
Affiliation:
|
Medical Department, Sandoz Prodotti Farmaceutici S.p.A, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
therapeutic use* Cholesterol / blood Cholesterol, HDL / blood Cholesterol, LDL / blood Double-Blind Method Fatty Acids, Monounsaturated / administration & dosage, therapeutic use* Female Humans Hydroxymethylglutaryl CoA Reductases / therapeutic use* Hydroxymethylglutaryl-CoA Reductase Inhibitors* Hypercholesterolemia / classification, drug therapy*, metabolism Indoles / administration & dosage, therapeutic use* Lipids / blood* Male Middle Aged Placebos Pravastatin / administration & dosage, therapeutic use* Single-Blind Method Thromboxane A2 / urine Thromboxane B2 / analogs & derivatives, urine Thromboxanes / urine* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/2,3-dinorthromboxane B1; 0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 0/Lipids; 0/Placebos; 0/Thromboxanes; 0/Triglycerides; 54397-85-2/Thromboxane B2; 57-88-5/Cholesterol; 57576-52-0/Thromboxane A2; 67910-12-7/11-dehydro-thromboxane B2; 81093-37-0/Pravastatin; 93957-54-1/fluvastatin; EC 1.1.1.-/Hydroxymethylglutaryl CoA Reductases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
Next Document: Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluva...